Solana (NASDAQ:HSDT) Posts Earnings Results, Misses Expectations By $0.03 EPS

Solana (NASDAQ:HSDT) posted its quarterly earnings results on Friday. The company reported ($0.05) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.02) by ($0.03), Zacks reports. Solana had a negative return on equity of 67.57% and a negative net margin of 1,427.15%.The firm had revenue of $2.53 million for the quarter, compared to analyst estimates of $3.50 million.

Here are the key takeaways from Solana’s conference call:

• Institutional infrastructure launched: Solana Company’s first validated cluster is operational in Tokyo, with approximately 500,000 SOL in committed third-party stake and validator-related revenue expected to begin in the third quarter.
• Staking performance remained strong: The company generated $2.5 million, or 31,200 SOL, in second-quarter staking revenue and achieved a 6.14% net annualized yield versus a network average of approximately 5.68%.
• Legacy-business transition advanced: The cash-consuming medical-device business was divested, while the company completed its acquisition of a Hong Kong regulated trust company on July 15 for $2 million to support its Asia-Pacific institutional strategy.
• GAAP losses remained substantial: The company reported a $30.3 million second-quarter net loss, including a $25.4 million realized loss on digital assets, while general and administrative expenses rose to $11.1 million, although management expects costs to decline as divestiture-related expenses end.
• Capital allocation will remain valuation-dependent: Solana Company repurchased $2.3 million of shares during the quarter while trading below net asset value, but management said future buybacks, SOL purchases, or business investment will depend on which option offers the greatest SOL-per-share accretion.

Solana Stock Performance

NASDAQ:HSDT traded down $0.10 during trading on Friday, reaching $1.70. The company’s stock had a trading volume of 137,150 shares, compared to its average volume of 106,755. The firm has a market cap of $99.26 million, a price-to-earnings ratio of -0.02 and a beta of 1.01. Solana has a 12 month low of $1.19 and a 12 month high of $25.50. The firm has a 50 day moving average of $1.67 and a 200-day moving average of $1.95.

Solana News Summary

Here are the key news stories impacting Solana this week:

• Positive Sentiment: Management expects to receive its first validator-related rewards in the third quarter of 2026. The company has committed approximately 0.5 million SOL to support its Tokyo validator cluster, potentially creating an additional recurring revenue stream. Solana Company expects first validator-related rewards in Q3 2026
• Positive Sentiment: Second-quarter revenue rose to approximately $2.5 million from $43,000 a year earlier, driven primarily by staking. Solana Company also earned 31,200 SOL in staking rewards, launched its first institutional validator cluster in Tokyo, expanded across Asia-Pacific, and completed the divestiture of its legacy PoNS medical-device business. Solana Company Reports Second Quarter 2026 Financial Results
• Positive Sentiment: The company raised $7.9 million through a registered direct offering and repurchased approximately $2.3 million of shares during the quarter. Partnerships with the Jito Foundation and organizations in Kazakhstan could support future infrastructure and advisory growth.
• Neutral Sentiment: Management’s earnings call emphasized a strategy built around SOL treasury growth, staking yield, validator infrastructure and advisory services, but future rewards and customer pipelines remain dependent on execution and digital-asset market conditions. Solana Company Q2 2026 Earnings Call Transcript
• Negative Sentiment: Profitability remained a major concern. Coverage cited an adjusted quarterly loss of $0.05 per share versus an expected loss of $0.02, while revenue of $2.53 million missed the $3.50 million consensus estimate. The company’s reported net loss was $30.3 million, with operating expenses of $35.1 million and general and administrative costs of $11.1 million. Solana Company Reports Q2 Loss, Lags Revenue Estimates
• Negative Sentiment: Wall Street Zen downgraded HSDT to “Sell,” adding to bearish sentiment. The company also held only $3.6 million in cash at quarter-end and reported a cumulative deficit of $342.6 million, underscoring financing and execution risks. Wall Street Zen Downgrades Solana to Sell

Wall Street Analyst Weigh In

HSDT has been the subject of several analyst reports. Wall Street Zen lowered shares of Solana from a “hold” rating to a “sell” rating in a report on Saturday. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Solana in a research report on Friday, July 17th. B. Riley Financial started coverage on Solana in a report on Thursday, April 23rd. They issued a “buy” rating and a $3.00 target price for the company. Finally, Zacks Research raised shares of Solana to a “hold” rating in a research note on Monday, April 27th. One analyst has rated the stock with a Strong Buy rating, one has assigned a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus target price of $3.50.

Institutional Investors Weigh In On Solana

Several institutional investors have recently added to or reduced their stakes in HSDT. Geode Capital Management LLC purchased a new stake in shares of Solana during the 4th quarter valued at approximately $1,006,000. LPL Financial LLC increased its stake in Solana by 120.1% in the 4th quarter. LPL Financial LLC now owns 382,255 shares of the company’s stock worth $1,105,000 after acquiring an additional 208,558 shares during the last quarter. State Street Corp purchased a new position in Solana in the 4th quarter worth approximately $464,000. Cetera Investment Advisers purchased a new position in Solana in the fourth quarter worth $347,000. Finally, Marshall Wace LLP bought a new stake in Solana during the fourth quarter worth about $195,000. 18.63% of the stock is owned by hedge funds and other institutional investors.

Solana Company Profile

Helius Medical Technologies, Inc (NASDAQ: HSDT) is a medical technology company focused on developing and commercializing non‐invasive neuromodulation platforms designed to enhance neurorehabilitation. Its flagship product, the Portable Neuromodulation Stimulator (PoNS®), delivers mild electrical pulses to the tongue to stimulate neural pathways in conjunction with targeted physical therapy. The device is intended to improve neuroplasticity and support recovery in patients with neurological conditions.

The PoNS system is cleared for use in the United States, Canada and the European Union and is prescribed through specialized rehabilitation clinics.